Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced the commercial availability of Crenessity™ (crinecerfont) in the United States. Crenessity, a first-in-class treatment for classic congenital adrenal hyperplasia (CAH), has been approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement for controlling androgens in adult and pediatric patients four years of age and older with classic CAH.
Crenessity, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that allows individuals to take lower doses of glucocorticoids while maintaining or improving their androgen levels.
To support patients with prescriptions, Crenessity is exclusively available through Pantherx Rare, a specialty pharmacy. Pantherx Rare has CAH-trained pharmacists available 24/7 to address questions and concerns from patients, caregivers, and healthcare providers.
Neurocrine Biosciences is committed to assisting patients in obtaining treatment with Crenessity through its Neurocrine Access Support program. This comprehensive assistance program is designed to ensure patients with CAH have the necessary support to begin and continue taking Crenessity. The company expects that 90% of patients will have a monthly copay of $12 or less.
Neurocrine Biosciences' CEO, Kyle W. Gano, Ph.D., emphasized the significance of Crenessity, stating that it provides a solution to the ongoing challenges faced by individuals with CAH and their families in managing the condition with high-dose steroids alone for the past 70 years.
The availability of Crenessity marks a significant milestone in the treatment landscape for classic CAH, offering a new option for patients and potentially improving their quality of life. As a result of these announcements, the company's shares have moved 0.7% on the market, and are now trading at a price of $135.96. Check out the company's full 8-K submission here.
